Ane Appelt/avl.nl
May 3, 2025, 14:50
Ane Appelt: Important results from the Skagen Trial 1 presented at ESTRO 2025
Ane Appelt, Associate Professor in Radiotherapy Physics at the University of Leeds, shared a post on X:
“Important (and puzzling) results from the Skagen Trial 1: Moderate hypofractionation for high-risk (node-positive) breast cancer patients does not increase arm lymphoedema – but is *does* seem to increase the breast-cancer related mortality.
Why? Not quite clear, but Prof Offersen speculates that the effective dose might simply be too low with 40Gy/15# for this group. (They’ve carefully confirmed that it’s not a question of RT quality!)”
ESTRO 2025 Live Updates on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 22:57
May 21, 2025, 21:13
May 21, 2025, 19:10
May 21, 2025, 18:49
May 21, 2025, 18:11
May 21, 2025, 18:05
May 21, 2025, 18:02